Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction
- PMID: 3051985
- DOI: 10.1016/0002-8703(88)90140-8
Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction
Abstract
The effect of early coronary artery reperfusion on ECG and enzymatic parameters was examined in 240 patients with acute myocardial infarction. These patients had participated in a randomized trial comparing intravenous anisoylated plasminogen streptokinase activator complex (APSAC) (n = 123) and intracoronary streptokinase (n = 117) therapy. Reperfusion occurred in 59 of 115 (51%) patients receiving APSAC and 67 of 111 (60%) patients receiving streptokinase (p = NS). There was greater early resolution of ST segment elevation in the reperfused than in the nonreperfused patients (p less than or equal to 0.003) and more rapid Q wave evolution (p less than or equal to 0.03). Sigma Q was lower in reperfused than in nonreperfused patients at 8 hours (1.41 +/- 1.18 versus 2.11 +/- 2.10 mV; p less than or equal to 0.05) and at 24 hours (1.43 +/- 1.25 mV versus 2.08 +/- 1.88 mV; p less than or equal to 0.02). Time to peak level was shorter in the reperfused patients for creatine kinase (CK) (10.7 +/- 5.5 hours versus 14.9 +/- 5.9 hours; p less than 0.0001) and lactic acid dehydrogenase (LDH) (29.6 +/- 13.6 hours versus 34.4 +/- 10.5 hours; less than or equal to 0.03) enzymes. Peak LDH-1 was lower in the reperfused group (274 +/- 149 U/L versus 341 +/- 173 U/L; p less than or equal to 0.04). Reperfusion at a mean of 3.9 hours after the onset of infarction was associated with more rapid resolution of ST segment elevation, faster Q wave evolution, smaller ECG infarct size, earlier cardiac enzyme release, and smaller enzymatic infarct size than later or no reperfusion.
Similar articles
-
Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.Drugs. 1987;33 Suppl 3:198-208. doi: 10.2165/00003495-198700333-00035. Drugs. 1987. PMID: 3315592 Clinical Trial.
-
Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.J Am Coll Cardiol. 1988 Jun;11(6):1153-63. doi: 10.1016/0735-1097(88)90276-8. J Am Coll Cardiol. 1988. PMID: 3284943 Clinical Trial.
-
Effects of early thrombolytic therapy (anistreplase versus streptokinase) on enzymatic and electrocardiographic infarct size in acute myocardial infarction. TEAM-2 Investigators.Am J Cardiol. 1991 Oct 1;68(9):848-56. doi: 10.1016/0002-9149(91)90398-5. Am J Cardiol. 1991. PMID: 1927942 Clinical Trial.
-
Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction.Am J Cardiol. 1989 Jul 5;64(2):12A-17A; discussion 24A-26A. doi: 10.1016/0002-9149(89)90923-5. Am J Cardiol. 1989. PMID: 2662737 Review.
-
Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.J Am Coll Cardiol. 1987 Nov;10(5 Suppl B):22B-27B. doi: 10.1016/s0735-1097(87)80424-2. J Am Coll Cardiol. 1987. PMID: 3312369 Review.
Cited by
-
French multicenter trial of anistreplase versus heparin in acute myocardial infarction.Cardiovasc Drugs Ther. 1990 Oct;4(5):1337-44. doi: 10.1007/BF02018261. Cardiovasc Drugs Ther. 1990. PMID: 2278869 Clinical Trial.
-
Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.Drugs. 1987;33 Suppl 3:198-208. doi: 10.2165/00003495-198700333-00035. Drugs. 1987. PMID: 3315592 Clinical Trial.
-
Acute coronary occlusion and reperfusion. Reliability of angiographic classification and grading.Drugs. 1987;33 Suppl 3:163-8. doi: 10.2165/00003495-198700333-00027. Drugs. 1987. PMID: 3315585 Clinical Trial.
-
Access to Timely and Optimal Care of Patients with Acute Coronary Syndromes - Community Planning Considerations: A Report by the National Heart Attack Alert Program.J Thromb Thrombolysis. 1998 Jul;6(1):19-46. doi: 10.1023/a:1008820104852. J Thromb Thrombolysis. 1998. PMID: 10753312
-
Serum myoglobin and creatine kinase enzymes in acute myocardial infarction treated with Anistreplase.J Clin Pathol. 1992 May;45(5):405-7. doi: 10.1136/jcp.45.5.405. J Clin Pathol. 1992. PMID: 1597518 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous